<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01893788</url>
  </required_header>
  <id_info>
    <org_study_id>Nagoya University</org_study_id>
    <nct_id>NCT01893788</nct_id>
  </id_info>
  <brief_title>Eplerenone and Aliskiren Research Targeting Hypertensive Patients With Left Ventricular Hypertrophy</brief_title>
  <acronym>EARTH</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Nagoya University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nagoya University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine which treatment will be more effective to
      reduce left ventricular mass in hypertensive patients with left ventricular hypertrophy
      comparing aliskiren and eplerenone.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2013</start_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>reduction of left ventricular hypertrophy measured by magnetic resonance imaging</measure>
    <time_frame>12 month</time_frame>
    <description>To compare the 12 month left ventricular mass or left ventricular mass and index measured by magnetic resonance imaging with baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular events</measure>
    <time_frame>12 month</time_frame>
    <description>total death, composite cardiovascular events, cardiac function eveluated by UCG,reduction of left ventricular hypertrophy measured by UCG</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Biochemical parameters</measure>
    <time_frame>12 month</time_frame>
    <description>BNP, PIIINP etc</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hypertensive Left Ventricular Hypertrophy</condition>
  <arm_group>
    <arm_group_label>Aliskiren</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aliskiren group treated with 150-300mg daily aliskiren without diuretics or ACE inhibitors or angiotensin receptor blockers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eplerenone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eplerenone group treated with 50-100mg daily eplerenone without diuretics or ACE inhibitors or angiotensin receptor blockers</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren</intervention_name>
    <description>Aliskiren: 150 to 300 mg daily for 48 weeks</description>
    <arm_group_label>Aliskiren</arm_group_label>
    <other_name>Rasilez</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eplerenone</intervention_name>
    <description>50 to 100 mg daily for 48 weeks</description>
    <arm_group_label>Eplerenone</arm_group_label>
    <other_name>Selara</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Male or female ≧ 20 years of age Clinical diagnosis of hypertension Patients who are able
        to provide written informed consent

        Exclusion Criteria:

          1. History of congestive heart failure, myocardial infarction, or coronary
             revascularization in the recent 6 months.

          2. Planned to taking percutaneous coronary intervention and coronary artery bypass graft

          3. Severe hypertension (≧ 180/110 mmHg) or secondary hypertension or malignant
             hypertension.

          4. History of stroke, cerebral hemorrhage, subarachnoid hemorrhage, transient ischemic
             attack in the recent 6 months

          5. Severe valvular heart disease or atrial fibrillation

          6. Congenital heart disease

          7. Severe heart failure (NYHA functional class Ⅳ)

          8. Current treatment with aliskiren or eplerenone or diuretics

          9. Taking potassium preparation or potassium-sparing diuretic

         10. Estimated GFR ≦ 30ml/min/1.73m２ at screening or current treatment with hemodialysis

         11. Potassium &gt; 5.0mEq/L at screening

         12. Diabetes mellitus with microalbuminuria or albuminuria

         13. Impairment of liver function (liver failure, liver cirrhosis)

         14. Pregnant woman or possibly pregnant woman

         15. History of malignant tumor include hematological neoplasm

         16. Current treatment with itraconazole, cyclosporin, ritonavir or nelfinavir

         17. Prior treatment with, hypersensitivity to, intolerance of or contra-indication to
             aliskiren and/or eplerenone

         18. Current participation in another clinical trial

         19. Serious non-cardiovascular disease severely limiting life expectancy

         20. Contra-indication to MRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Toyoaki Murohara, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology, Nagoya University Graduate School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Cardiology, Nagoya University Graduate School of Medicine</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>466-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takanori Nagahiro, MD</last_name>
      <phone>81-52-744-2149</phone>
      <email>t-nagahiro@med.nagoya-u.ac.jp</email>
    </contact>
    <contact_backup>
      <last_name>Toyoaki Murohara, MD, PhD</last_name>
      <phone>81-52-744-2149</phone>
      <email>murohara@med.nagoya-u.ac.jp</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2013</study_first_submitted>
  <study_first_submitted_qc>July 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2013</study_first_posted>
  <last_update_submitted>July 18, 2013</last_update_submitted>
  <last_update_submitted_qc>July 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nagoya University</investigator_affiliation>
    <investigator_full_name>TOYOAKI MUROHARA</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>hypertension</keyword>
  <keyword>left ventricular hypertrophy</keyword>
  <keyword>renin angiotensin system</keyword>
  <keyword>aldosterone</keyword>
  <keyword>aliskiren</keyword>
  <keyword>eplerenone</keyword>
  <keyword>P3NP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Hypertrophy, Left Ventricular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eplerenone</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
    <mesh_term>Angiotensin Receptor Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

